• Publications
  • Influence
Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
TLDR
Tissue kinetics of a small molecule inhibitor of PSMA using PET/CT to estimate radiation dosimetry for the potential therapeutic use of 131I-MIP-1095 in men with mCRPC enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions. Expand
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
TLDR
Compared with the standard-of-care bone scanning, 99mTc-MIP-1404 and 99mMip-1405 identified most bone metastatic lesions and rapidly detected soft-tissue PCa lesions including subcentimeter lymph nodes. Expand
The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?
TLDR
DUR can vary widely with the time of measurement and that DUR should be interpreted with caution in any individual patient, according to the data investigated. Expand
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer
TLDR
These 99mTc-labeled radiopharmaceuticals targeting PSMA may provide a SPECT molecular imaging option to assist in the initial diagnosis of prostate cancer and the management of patient care by monitoring disease progression. Expand
I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
TLDR
The tissue kinetics of a small molecule inhibitor of PSMA is investigated using PET/CT to estimate radiation dosimetry for the potential therapeutic use of 131 I-MIP-1095 in men with mCRPC. Expand
A ticket to ride: peptide radiopharmaceuticals.
TLDR
Many of the parameters for the rational development of peptide-based imaging agents are described, including: classes of peptides for imaging, methods for radiolabeling peptides, current biologically active peptides-based radiopharmaceuticals and future prospects for this new technology. Expand
Mapping of local renal blood flow with PET and H(2)(15)O.
TLDR
Parametric mapping of RBF with PET and H(2)(15)O provides a straightforward, noninvasive method for quantitative mapping ofRBF, which may prove useful in research applications and in the management of patients whose therapy alters renal tubular transport. Expand
Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide 131I-BA52
TLDR
Systemic radionuclide therapy using 131I-BA52 as a novel approach for the therapy of malignant melanoma is of considerable potential, and future trials should be done to enhance the precision of dosimetry, validate the maximum tolerable dose, and evaluate the effectiveness of the treatment in a prospective manner. Expand
Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy.
TLDR
It is demonstrated that MIBG accumulation in the heart showed a greater and more linear dose-dependent decrease than LVEF, which may be a sensitive biochemical marker of adriamycin cardiomyopathy. Expand
Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.
TLDR
The versatile intermediate 2-[3-(5-amino-1-carboxy-pentyl)-ureido]-pentanedioic acid (Lys-C(O)-Glu) is used to extend the development of new imaging agents targeting the prostate-specific membrane antigen (PSMA) with clear delineation of the tumor by SPECT. Expand
...
1
2
3
4
5
...